ElmediX
Updated: December 05, 2025
John-Paul Bogers, CEO
Country: Belgium | Funding: €4M (+)
Founded: 2015
Website: https://www.elmedix.com/
ElmediX is developing thermotherapy for the treatment of pancreatic cancer. This treatment method involves raising the patient's body temperature to 41.5°C for a period of time to strengthen the immune system, suppress tumor growth and enhance sensitivity to other anticancer drugs. Thermotherapy is toxic to cells in a hypoxic, low-pH environment, particularly typical of tumor tissue, due to insufficient blood perfusion. Heat increases permeability and blood flow in the tumor stroma, enhancing oxidative damage to cancer cells and the resorption of anticancer drugs by cancer cells. This enhances the effectiveness of chemotherapy and has been demonstrated in several recent clinical trials.
Founded: 2015
Website: https://www.elmedix.com/
ElmediX is developing thermotherapy for the treatment of pancreatic cancer. This treatment method involves raising the patient's body temperature to 41.5°C for a period of time to strengthen the immune system, suppress tumor growth and enhance sensitivity to other anticancer drugs. Thermotherapy is toxic to cells in a hypoxic, low-pH environment, particularly typical of tumor tissue, due to insufficient blood perfusion. Heat increases permeability and blood flow in the tumor stroma, enhancing oxidative damage to cancer cells and the resorption of anticancer drugs by cancer cells. This enhances the effectiveness of chemotherapy and has been demonstrated in several recent clinical trials.
